Cognition Therapeutics Company Insiders
| CGTX Stock | USD 0.45 0.02 4.65% |
Cognition Therapeutics' insiders are aggressively buying. The analysis of the overall insider sentiment regarding Cognition Therapeutics suggests that vertually all insiders are extremely bullish. Cognition Therapeutics employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-03-14 | Lisa Ricciardi | Acquired 5700 @ 1.75 | View | ||
| 2022-11-29 | Ellen B Richstone | Acquired 10000 @ 2.65 | View | ||
| 2022-11-15 | Peggy Wallace | Acquired 12500 @ 1.2 | View |
Monitoring Cognition Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Cognition |
Cognition Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (1.0315) % which means that it has lost $1.0315 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5719) %, meaning that it created substantial loss on money invested by shareholders. Cognition Therapeutics' management efficiency ratios could be used to measure how well Cognition Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.18 in 2025. Return On Capital Employed is likely to drop to -2.97 in 2025. At this time, Cognition Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 48.6 M in 2025, despite the fact that Non Currrent Assets Other are likely to grow to (0.85).Common Stock Shares Outstanding is likely to drop to about 30.2 M in 2025. Net Loss is likely to drop to about (20.2 M) in 2025
Cognition Therapeutics Workforce Comparison
Cognition Therapeutics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,463. Cognition Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Cognition Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cognition Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cognition Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cognition Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cognition Therapeutics Notable Stakeholders
A Cognition Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cognition Therapeutics often face trade-offs trying to please all of them. Cognition Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cognition Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lisa Ricciardi | President CEO | Profile | |
| Steven Weissman | VP CMC | Profile | |
| Bobby Horn | Corporate Controller | Profile | |
| Andrew CPA | Interim Officer | Profile | |
| John Doyle | Chief Officer | Profile | |
| Anita Cornet | Head Quality | Profile |
About Cognition Therapeutics Management Performance
The success or failure of an entity such as Cognition Therapeutics often depends on how effective the management is. Cognition Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cognition management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cognition management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.12) | (1.18) | |
| Return On Capital Employed | (2.83) | (2.97) | |
| Return On Assets | (1.12) | (1.18) | |
| Return On Equity | (1.81) | (1.72) |
Please note, the imprecision that can be found in Cognition Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cognition Therapeutics. Check Cognition Therapeutics' Beneish M Score to see the likelihood of Cognition Therapeutics' management manipulating its earnings.
Cognition Therapeutics Workforce Analysis
Traditionally, organizations such as Cognition Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cognition Therapeutics within its industry.Cognition Therapeutics Manpower Efficiency
Return on Cognition Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.7M | |
| Net Loss Per Executive | 5.7M | |
| Working Capital Per Employee | 3.1M | |
| Working Capital Per Executive | 3.1M |
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.